Access Financial Services Inc. Decreases Stock Position in Pfizer Inc. (NYSE:PFE)

Access Financial Services Inc. trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 15.8% during the 4th quarter, HoldingsChannel.com reports. The firm owned 41,683 shares of the biopharmaceutical company’s stock after selling 7,835 shares during the quarter. Access Financial Services Inc.’s holdings in Pfizer were worth $1,200,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the business. Worth Asset Management LLC bought a new stake in shares of Pfizer in the first quarter worth approximately $29,000. Briaud Financial Planning Inc purchased a new position in shares of Pfizer in the 3rd quarter worth $30,000. GoalVest Advisory LLC grew its holdings in shares of Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 811 shares during the period. Mizuho Securities Co. Ltd. bought a new position in Pfizer in the third quarter valued at about $34,000. Finally, VisionPoint Advisory Group LLC boosted its position in Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. UBS Group dropped their price objective on shares of Pfizer from $34.00 to $27.00 and set a “neutral” rating on the stock in a report on Thursday, December 14th. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Truist Financial lowered their target price on Pfizer from $42.00 to $36.00 and set a “buy” rating on the stock in a research report on Thursday, December 14th. Guggenheim began coverage on Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Friday, March 1st. Twelve research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $36.88.

Pfizer Stock Down 0.1 %

Shares of NYSE:PFE opened at $27.75 on Friday. The stock has a market cap of $157.14 billion, a P/E ratio of 77.08, a price-to-earnings-growth ratio of 1.24 and a beta of 0.61. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a 52-week low of $25.61 and a 52-week high of $42.22. The business’s 50 day moving average is $27.46 and its 200 day moving average is $29.46.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The business had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company’s revenue was down 41.3% compared to the same quarter last year. During the same period last year, the business earned $1.14 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.22 EPS for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.